Rock Springs Capital led a $95m Series C funding round in Xilio Therapeutics, a biotechnology company. Additional investors include Bain Capital Life Sciences, Deerfield Management Company, RA Capital Management, Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners, and MRL Ventures Fund. "The support from Rock Springs Capital and this world-class group of investors is a testament to our unique tumor-selective technology and the expertise of the team we have built, all of whom share our vision to transform the lives of people living with cancer. his financing provides us with additional capital to execute our clinical development plans for XTX202 and XTX101, as well as to advance our cytokine pipeline, including our tumor-selective IL-12, XTX301," Rene Russo, Xilio CEO.